GlassScriptPhysician profile
Ali K Murad
NPI 1811103831
$4,961.01
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $422 · 2021: $1,960 · 2022: $1,705 · 2023: $66.36 · 2024: $76.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $2,860.80 | 2021-2022 | |
| Nevro Corp. | $1,696.89 | 2019-2023 | Senza |
| Stryker Corporation | $212.60 | 2019-2024 | Universal Neuro 3, N/A |
| Zimmer Biomet Holdings, INC. | $92.40 | 2019 | |
| Canon Medical Systems USA, INC. | $27.76 | 2022 | |
| Integra Lifesciences Corporation | $27.06 | 2019 | |
| Orthofix Medical, INC. | $17.52 | 2019 | |
| Ctl Medical Corporation | $13.92 | 2023 | Spinal |
| Olympus America INC. | $12.06 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,715,761.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.